Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of BA1302 in Patients With Advanced Solid Malignancies

NCT06596915 is registered in ClinicalTrials.gov with Shandong Boan Biotechnology Co., Ltd as lead sponsor.

NCT NCT06596915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06596915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of BA1302 in Patients With Advanced Solid Malignancies
Lead sponsor
Shandong Boan Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
September 11, 2024
Completion date
December 31, 2027
Enrollment
167 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, melanoma, non-small cell lung cancer, pancreatic adenocarcinoma